Screener
Immunome IMNM EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Immunome’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
FAQ
- What is Immunome's EPS (diluted)?
- Immunome (IMNM) reported EPS (diluted) of -$0.48 in Q1 2026.
- How has Immunome's EPS (diluted) changed year-over-year?
- Immunome's EPS (diluted) increased by 7.7% year-over-year, from -$0.52 to -$0.48.
- What is the long-term trend for Immunome's EPS (diluted)?
- Over 4 years (2021 to 2025), Immunome's EPS (diluted) has grown at a 3.2% compound annual growth rate (CAGR), from -$2.13 to -$2.42.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Immunome's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude